Engineers Gate Manager LP Macrogenics Inc Transaction History

Engineers Gate Manager LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $87,428 - $142,686	-18,924 Reduced 46.27%	21,976 $117,000
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $11,086 - $16,652	2,300 Added 5.96%	40,900 $293,000
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $128,924 - $269,428	38,600 New	38,600 $259,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $83,702 - $371,637	37,201 Added 85.95%	80,485 $237,000
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $351,466 - $731,499	43,284 New	43,284 $381,000
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $300,858 - $413,750	-18,910 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $373,283 - $542,717	18,910 New	18,910 $396,000
Q1 2020 May 15, 2020	SELL	$4.28 - $12.11 $101,397 - $286,898	-23,691 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.95 - $12.27 $188,343 - $290,688	23,691 New	23,691 $258,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.